WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Omeros Corporation
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Cell and Gene Therapy, Industrial Impact
Exelixis | February 14, 2023
On February 13, 2023, Exelixis, Inc., a leading global oncology firm innovating next-generation medicines and regimens at the forefront of cancer care and Sairopa B.V. (Sairopa), a renowned firm developing novel therapeutics for cancer by modulating the patient's immune system, announced that FDA has approved Sairopa's Investigational New Drug (IND) Application to assess the pharmacokinetics and safety of ADU-1805 in adults with advanced solid tumors. ADU-1805, being a m...
Tevogen Bio | August 11, 2020
Tevogen Bio believes that its investigational highly purified antigen-specific T cell therapy holds promise in the treatment of viral infections including COVID-19 and Influenza A. This collaboration aims to harness Tevogen's proprietary immunotherapy platform and Dr. Flomenberg's expertise in immunology, histocompatibility and pioneering work in the immunology of stem cell transplantation. Tevogen Bio announces a joint partnership with renowned bone-marrow transplant expert Neal Flomenb...
Industrial Impact
Antheia | August 13, 2021
Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, today announced a partnership to accelerate the development and production of essential medicines. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ: SRNG), serves customers across industries seeking to develop new and better products. Antheia plans to leverage Ginkgo...
Medical
CellCarta | May 23, 2022
CellCarta, a leading global provider of precision medicine laboratory services, announced today the acquisition of the commercial rights to the antibody panels and assays from Precision Assays, a leader in next-generation targeted proteomics testing solutions. A spin-off from Fred Hutchinson Cancer Center ("Fred Hutch"), Precision Assays develops and deploys high-end multiplex quantitative immuno-MRM mass spectrophotometry-based assays for its pharmaceutical and biotech industry client...
Industry Outlook
Whitepaper
MedTech
Video
Research, Medical
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE